Ratings · Founded 1993 · www.careedge.in · BSE 534804 · NSE CARERATING · ISIN INE752H01013
No Notes Added Yet
Business
Care Ratings Ltd. is a leading credit rating agency in India. Its core business involves assessing and assigning credit ratings to various debt instruments, bank loans, and other financial obligations of corporates, financial institutions, and public sector undertakings. It also provides ratings for initial public offerings (IPOs), corporate governance, infrastructure projects, mutual funds, and small and medium enterprises (SMEs). The company primarily makes money by charging fees to its clients (issuers) for these rating and grading services.
Revenue Mix
Care Ratings operates primarily in the credit rating segment. Its revenue is predominantly derived from fees charged for assigning and monitoring credit ratings across a wide spectrum of instruments and entities. This includes corporate bond ratings, bank loan ratings, structured finance ratings, ratings for public finance, project finance, financial sector entities, and various grading assignments (e.g., IPO grading, governance ratings, real estate project ratings). While it may offer research and advisory services, the overwhelming majority of its revenue comes from its core rating business. Specific revenue breakdowns by instrument or client type are typically detailed in their annual reports.
Industry
The Indian credit rating industry is a highly regulated oligopoly, dominated by a few key players. Care Ratings is one of the top three or four significant credit rating agencies in India, alongside CRISIL (an S&P Global company), ICRA (a Moody's Investors Service company), and India Ratings & Research (a Fitch Group company). Care Ratings has established itself as a credible player with a significant market share, particularly in rating bank loans and various debt instruments, making it a prominent competitor to the larger, globally-affiliated agencies.
MOAT
Regulatory Barriers: The credit rating industry is highly regulated by SEBI, requiring stringent compliance and significant capital. This acts as a high entry barrier for new players.
Reputation and Credibility: Trust, independence, and an unblemished track record are paramount in the ratings business. Care Ratings, having operated for decades, has built a significant reputation and credibility among investors, issuers, and regulators.
Data and Analytical Expertise: Accumulated historical data, proprietary methodologies, and deep analytical expertise contribute to its competitive edge, making it difficult for new entrants to replicate.
Moderate Switching Costs: While not extremely high, issuers often prefer continuity with an established rating agency due to familiarity with processes, methodologies, and the agency's acceptance by lenders/investors.
Growth Drivers
Indian Economic Growth: A growing economy generally leads to increased corporate borrowing, capital expenditure, and new debt issuances, driving demand for credit ratings.
Deepening of Bond Market: Efforts by regulators to deepen India's corporate bond market will result in more companies raising capital through bonds, increasing the need for bond ratings.
Regulatory Mandates: Evolving SEBI and RBI regulations, such as mandatory credit ratings for bank loan exposures and certain market instruments, continuously expand the addressable market.
Infrastructure Spending: Government thrust on infrastructure development will necessitate project financing and related credit assessments.
Financialization of Economy: Increased formalization and reliance on structured finance will lead to a higher demand for various rating and grading services.
Risks
Reputational Risk: Any failure in accurately assessing creditworthiness, or perceived conflicts of interest, can severely damage credibility and lead to loss of business and regulatory scrutiny.
Intense Competition: The industry faces fierce competition from larger, globally-backed players (CRISIL, ICRA, India Ratings) who often have deeper pockets and wider international recognition.
Regulatory Changes: Adverse changes in SEBI regulations, fee caps, or increased compliance burdens could impact profitability and business models.
Economic Downturn: A slowdown in economic activity can reduce corporate borrowing and new debt issuances, negatively impacting revenue generation.
Cyclicality: The rating business is somewhat cyclical, tied to credit cycles and capital market activity.
Talent Retention: Attracting and retaining experienced credit analysts is crucial, and a competitive labor market poses a challenge.
Management & Ownership
Care Ratings Ltd. was initially promoted by leading financial institutions like IDBI Bank. Over time, it has evolved into a professionally managed, publicly listed company. While it does not have a single dominant promoter group in the traditional sense, it has a diversified ownership structure with institutional investors, corporate bodies, and public shareholders. The company typically operates with an independent board and experienced professionals, aiming for governance standards aligned with its role as a financial market utility.
Outlook
Care Ratings operates in a stable, regulated oligopolistic industry, benefiting from India's economic growth and deepening financial markets. The increasing formalization of the economy, regulatory push for ratings, and growth in debt capital markets provide a favorable backdrop for consistent revenue generation. However, it faces intense competition from larger, globally-affiliated peers who often have greater resources and market penetration. The inherent reputational risks of the credit rating business necessitate strong governance and analytical rigor. Its ability to maintain its independence, enhance analytical capabilities, and navigate competitive pressures while adhering to regulatory standards will be key determinants of its continued success.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 90 | 79 | 117 | 96 | 110 | 94 | 136 | 112 | 131 | 112 |
| Other Income | 10 | 12 | 12 | 12 | 15 | 14 | 13 | 13 | 16 | 15 |
| Total Income | 100 | 91 | 129 | 108 | 125 | 108 | 149 | 125 | 146 | 126 |
| Total Expenditure | 61 | 57 | 62 | 66 | 62 | 66 | 68 | 72 | 70 | 77 |
| Operating Profit | 39 | 34 | 68 | 42 | 63 | 41 | 81 | 53 | 76 | 49 |
| Interest | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 36 | 30 | 64 | 39 | 59 | 37 | 77 | 49 | 72 | 45 |
| Provision for Tax | 12 | 9 | 17 | 10 | 16 | 11 | 20 | 12 | 19 | 12 |
| Profit After Tax | 25 | 21 | 47 | 28 | 43 | 26 | 57 | 37 | 53 | 33 |
| Adjustments | -0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 |
| Profit After Adjustments | 24 | 21 | 46 | 28 | 43 | 26 | 57 | 36 | 53 | 32 |
| Adjusted Earnings Per Share | 8.1 | 6.9 | 15.4 | 9.3 | 14.2 | 8.6 | 18.9 | 12 | 17.6 | 10.7 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 279 | 287 | 333 | 319 | 244 | 248 | 248 | 279 | 332 | 402 | 473 | 491 |
| Other Income | 9 | 34 | 25 | 30 | 31 | 31 | 27 | 38 | 47 | 51 | 55 | 57 |
| Total Income | 288 | 321 | 358 | 349 | 275 | 280 | 275 | 317 | 378 | 453 | 528 | 546 |
| Total Expenditure | 105 | 105 | 122 | 144 | 162 | 153 | 168 | 180 | 220 | 247 | 276 | 287 |
| Operating Profit | 183 | 216 | 236 | 205 | 113 | 127 | 107 | 137 | 159 | 206 | 252 | 259 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 2 | 2 | 2 | 4 |
| Depreciation | 4 | 3 | 3 | 3 | 8 | 8 | 8 | 11 | 10 | 12 | 14 | 15 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 178 | 212 | 233 | 202 | 104 | 119 | 99 | 126 | 147 | 192 | 235 | 243 |
| Provision for Tax | 59 | 65 | 71 | 64 | 21 | 28 | 22 | 40 | 44 | 52 | 62 | 63 |
| Profit After Tax | 120 | 148 | 162 | 138 | 83 | 91 | 77 | 85 | 103 | 140 | 174 | 180 |
| Adjustments | 0 | 0 | 0 | -1 | -1 | -1 | -2 | -2 | -2 | -3 | -3 | -4 |
| Profit After Adjustments | 120 | 148 | 162 | 137 | 82 | 90 | 75 | 84 | 101 | 137 | 171 | 178 |
| Adjusted Earnings Per Share | 40.7 | 50.1 | 55.1 | 46.7 | 28 | 30.4 | 25.3 | 28.1 | 33.7 | 45.9 | 57 | 59.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 18% | 19% | 14% | 5% |
| Operating Profit CAGR | 22% | 23% | 15% | 3% |
| PAT CAGR | 24% | 27% | 14% | 4% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 3% | 19% | 18% | 1% |
| ROE Average | 20% | 18% | 16% | 21% |
| ROCE Average | 27% | 25% | 22% | 29% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 409 | 520 | 597 | 550 | 533 | 589 | 647 | 672 | 717 | 806 | 932 |
| Minority's Interest | 0 | 0 | 2 | 2 | 3 | 4 | 5 | 7 | 7 | 9 | 11 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 371 | 15 | 9 | 13 | 22 | 25 | 21 | 33 | 38 | 44 | 44 |
| Total Current Liabilities | 86 | 475 | 551 | 611 | 541 | 557 | 584 | 58 | 79 | 98 | 118 |
| Total Liabilities | 866 | 1010 | 1159 | 1177 | 1099 | 1175 | 1257 | 770 | 842 | 958 | 1105 |
| Fixed Assets | 64 | 61 | 60 | 83 | 93 | 85 | 96 | 107 | 109 | 119 | 122 |
| Other Non-Current Assets | 593 | 83 | 257 | 252 | 229 | 40 | 65 | 61 | 58 | 146 | 305 |
| Total Current Assets | 209 | 866 | 842 | 842 | 777 | 1050 | 1096 | 602 | 675 | 692 | 677 |
| Total Assets | 866 | 1010 | 1159 | 1177 | 1099 | 1175 | 1257 | 770 | 842 | 958 | 1105 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 13 | 12 | 13 | 24 | 20 | 7 | 12 | 18 | 49 | 38 | 49 |
| Cash Flow from Operating Activities | 106 | 119 | 134 | 109 | 67 | 86 | 68 | 82 | 91 | 123 | 148 |
| Cash Flow from Investing Activities | -41 | -22 | -25 | 83 | 27 | -38 | -27 | 13 | -39 | -58 | -94 |
| Cash Flow from Financing Activities | -66 | -96 | -99 | -195 | -107 | -43 | -35 | -63 | -63 | -54 | -59 |
| Net Cash Inflow / Outflow | -1 | 1 | 11 | -4 | -13 | 5 | 6 | 32 | -11 | 11 | -6 |
| Closing Cash & Cash Equivalent | 12 | 13 | 24 | 20 | 7 | 12 | 18 | 49 | 38 | 49 | 43 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 40.68 | 50.13 | 55.13 | 46.66 | 27.96 | 30.38 | 25.33 | 28.12 | 33.67 | 45.85 | 56.97 |
| CEPS(Rs) | 42.1 | 51.27 | 56.17 | 47.99 | 30.97 | 33.52 | 28.51 | 32.32 | 37.87 | 50.69 | 62.59 |
| DPS(Rs) | 28 | 28 | 55 | 30 | 19.5 | 17 | 17 | 25 | 18 | 18 | 22 |
| Book NAV/Share(Rs) | 138.53 | 176.5 | 199.65 | 179.42 | 173.02 | 191.49 | 215.75 | 224.16 | 238.52 | 267.56 | 308.68 |
| Core EBITDA Margin(%) | 62.24 | 63.39 | 63.35 | 54.76 | 33.38 | 38.55 | 32.15 | 35.61 | 33.81 | 38.61 | 41.73 |
| EBIT Margin(%) | 63.86 | 73.93 | 70.06 | 63.24 | 43.1 | 48 | 40.02 | 45.43 | 44.72 | 48.31 | 50.28 |
| Pre Tax Margin(%) | 63.86 | 73.93 | 70.06 | 63.24 | 42.72 | 47.76 | 39.83 | 45.07 | 44.21 | 47.79 | 49.75 |
| PAT Margin (%) | 42.81 | 51.36 | 48.8 | 43.29 | 34.26 | 36.61 | 31.03 | 30.63 | 30.92 | 34.8 | 36.72 |
| Cash Profit Margin (%) | 44.31 | 52.54 | 49.74 | 44.33 | 37.45 | 39.75 | 34.14 | 34.4 | 34.08 | 37.71 | 39.75 |
| ROA(%) | 14.82 | 15.74 | 14.97 | 11.82 | 7.34 | 8 | 6.32 | 8.43 | 12.73 | 15.56 | 16.84 |
| ROE(%) | 31.49 | 31.85 | 29.3 | 24.73 | 16.08 | 16.94 | 12.76 | 13.09 | 14.89 | 18.51 | 20.1 |
| ROCE(%) | 46.48 | 45.76 | 41.74 | 35.18 | 19.39 | 21.26 | 16.03 | 19.21 | 21.35 | 25.52 | 27.36 |
| Receivable days | 25.71 | 31.06 | 35.4 | 49.49 | 66.03 | 45.73 | 28 | 24.22 | 23.59 | 24.75 | 25.89 |
| Inventory Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Payable days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PER(x) | 22.92 | 33.06 | 21.96 | 21.18 | 11.79 | 13.53 | 20.21 | 22.86 | 33.18 | 24.01 | 25.27 |
| Price/Book(x) | 6.73 | 9.39 | 6.06 | 5.51 | 1.9 | 2.15 | 2.37 | 2.87 | 4.68 | 4.11 | 4.66 |
| Dividend Yield(%) | 3 | 1.69 | 4.54 | 3.04 | 5.92 | 4.13 | 3.32 | 3.89 | 1.61 | 1.64 | 1.53 |
| EV/Net Sales(x) | 9.77 | 16.93 | 10.63 | 9.03 | 3.51 | 3.71 | 5.8 | 6.64 | 9.88 | 7.95 | 8.87 |
| EV/Core EBITDA(x) | 14.94 | 22.54 | 14.98 | 14.05 | 7.59 | 7.25 | 13.45 | 13.5 | 20.63 | 15.52 | 16.64 |
| Net Sales Growth(%) | 7.22 | 2.89 | 15.74 | -4.12 | -23.62 | 1.97 | -0.33 | 12.66 | 18.89 | 21.3 | 17.59 |
| EBIT Growth(%) | -9.98 | 19.11 | 9.69 | -13.45 | -47.94 | 13.56 | -16.91 | 27.91 | 17.04 | 31.03 | 22.36 |
| PAT Growth(%) | -13.22 | 23.42 | 9.97 | -14.95 | -39.54 | 8.97 | -15.54 | 11.23 | 20.02 | 36.5 | 24.07 |
| EPS Growth(%) | -14.41 | 23.24 | 9.97 | -15.36 | -40.08 | 8.67 | -16.62 | 11.01 | 19.74 | 36.16 | 24.25 |
| Debt/Equity(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 2.43 | 1.82 | 1.53 | 1.38 | 1.44 | 1.88 | 1.88 | 10.41 | 8.57 | 7.08 | 5.76 |
| Quick Ratio(x) | 2.43 | 1.82 | 1.53 | 1.38 | 1.44 | 1.88 | 1.88 | 10.41 | 8.57 | 7.08 | 5.76 |
| Interest Cover(x) | 0 | 0 | 0 | 0 | 113.23 | 193.14 | 213.66 | 126.55 | 86.65 | 92.2 | 95.67 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FII | 23.37 | 24.8 | 24.75 | 23.74 | 24.62 | 23.61 | 23 | 23.25 | 23.41 | 23.6 |
| DII | 26.15 | 25.28 | 27.51 | 29.38 | 29.76 | 31.6 | 31.3 | 31.39 | 31.58 | 32.22 |
| Public | 50.48 | 49.93 | 47.74 | 46.88 | 45.62 | 44.79 | 45.7 | 45.37 | 45.01 | 44.18 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FII | 0.7 | 0.74 | 0.74 | 0.71 | 0.74 | 0.71 | 0.69 | 0.7 | 0.7 | 0.71 |
| DII | 0.78 | 0.76 | 0.82 | 0.88 | 0.89 | 0.95 | 0.94 | 0.94 | 0.95 | 0.97 |
| Public | 1.51 | 1.49 | 1.43 | 1.4 | 1.37 | 1.34 | 1.37 | 1.36 | 1.35 | 1.33 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.99 | 2.99 | 2.99 | 2.99 | 3 | 3 | 3 | 3 | 3.01 | 3.01 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +18% | +19% | +14% | +5% |
| Operating Profit CAGR | +22% | +23% | +15% | +3% |
| PAT CAGR | +24% | +27% | +14% | +4% |
| Share Price CAGR | +3% | +19% | +18% | +1% |
| ROE Average | +20% | +18% | +16% | +21% |
| ROCE Average | +27% | +25% | +22% | +29% |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FII | 23.37 | 24.8 | 24.75 | 23.74 | 24.62 | 23.61 | 23 | 23.25 | 23.41 | 23.6 |
| DII | 26.15 | 25.28 | 27.51 | 29.38 | 29.76 | 31.6 | 31.3 | 31.39 | 31.58 | 32.22 |
| Public | 50.48 | 49.93 | 47.74 | 46.88 | 45.62 | 44.79 | 45.7 | 45.37 | 45.01 | 44.18 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FII | 0.7 | 0.74 | 0.74 | 0.71 | 0.74 | 0.71 | 0.69 | 0.7 | 0.7 | 0.71 |
| DII | 0.78 | 0.76 | 0.82 | 0.88 | 0.89 | 0.95 | 0.94 | 0.94 | 0.95 | 0.97 |
| Public | 1.51 | 1.49 | 1.43 | 1.4 | 1.37 | 1.34 | 1.37 | 1.36 | 1.35 | 1.33 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.99 | 2.99 | 2.99 | 2.99 | 3 | 3 | 3 | 3 | 3.01 | 3.01 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.